{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:51:52Z","timestamp":1788015112726,"version":"build-2784847793"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jaci.2021.12.759","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T21:53:28Z","timestamp":1643406808000},"page":"1675-1682.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER)"],"prefix":"10.1016","volume":"149","author":[{"given":"Philippe","family":"Gevaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Bachert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Fernando","family":"Maspero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Cuevas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Altman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2021.12.759_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European position paper on rhinosinusitis and nasal polyps, 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jaci.2021.12.759_bib2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jaci.2020.01.020","article-title":"Biologics for chronic rhinosinusitis with nasal polyps","volume":"145","author":"Bachert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.759_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jaci.2020.04.040","article-title":"Type 2 inflammation in chronic rhinosinusitis without nasal polyps: another relevant endotype","volume":"146","author":"Delemarre","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"suppl\u00a01","key":"10.1016\/j.jaci.2021.12.759_bib4","first-page":"S22","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis","volume":"6","author":"Orlandi","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2021.12.759_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program","volume":"181","author":"Moore","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2021.12.759_bib6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.anai.2014.07.025","article-title":"Diagnosis and management of rhinosinusitis: a practice parameter update","volume":"113","author":"Peters","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2021.12.759_bib7","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/archotol.133.7.693","article-title":"Expression of prostaglandin D2 synthase in activated eosinophils in nasal polyps","volume":"133","author":"Hyo","year":"2007","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jaci.2021.12.759_bib8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/alr.21021","article-title":"Increased percentage of mast cells within sinonasal mucosa of chronic rhinosinusitis with nasal polyp patients independent of atopy","volume":"2","author":"Shaw","year":"2012","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2021.12.759_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.prostaglandins.2003.12.002","article-title":"Expression of prostaglandin D synthase and the prostaglandin D2 receptors DP and CRTH2 in human nasal mucosa","volume":"73","author":"Nantel","year":"2004","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.jaci.2021.12.759_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2018.08.001","article-title":"Prostaglandins in asthma and allergic diseases","volume":"193","author":"Peebles","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jaci.2021.12.759_bib11","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1398-9995.2009.02204.x","article-title":"CRTH2 mediates the activation of human Th2 cells in response to PGD2 released from IgE\/anti-IgE treated nasal polyp tissue","volume":"65","author":"Perez-Novo","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.12.759_bib12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.clim.2014.09.007","article-title":"Increased ILC2s in the eosinophilic nasal polyp endotype are associated with corticosteroid responsiveness","volume":"155","author":"Walford","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.759_bib13","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ni.2104","article-title":"Human IL-25\u2013 and IL-33\u2013responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161","volume":"12","author":"Mj\u00f6sberg","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2021.12.759_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000155743","article-title":"Expression and characterization of PGD2 receptors in chronic rhinosinusitis: modulation of DP and CRTH2 by PGD2","volume":"148","author":"Yamamoto","year":"2009","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.12.759_bib15","doi-asserted-by":"crossref","first-page":"738s","DOI":"10.1177\/0145561320902858","article-title":"Steroids inhibit eosinophil accumulation and downregulate hematopoietic chemotaxic prostaglandin D2 receptor in aspirin-exacerbated respiratory disease","volume":"100","author":"Suzuki","year":"2021","journal-title":"Ear Nose Throat J"},{"key":"10.1016\/j.jaci.2021.12.759_bib16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1124\/mol.115.101832","article-title":"Fevipiprant (QAW039), a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy","volume":"89","author":"Sykes","year":"2016","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jaci.2021.12.759_bib17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pupt.2016.06.005","article-title":"The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma","volume":"39","author":"Erpenbeck","year":"2016","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaci.2021.12.759_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/13993003.00670-2017","article-title":"Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids","volume":"50","author":"Bateman","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2021.12.759_bib19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(16)30179-5","article-title":"Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial","volume":"4","author":"Gonem","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2021.12.759_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2213-2600(20)30412-4","article-title":"Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials","volume":"9","author":"Brightling","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2021.12.759_bib21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2021.12.759_bib22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.759_bib23","doi-asserted-by":"crossref","first-page":"100847","DOI":"10.1016\/j.eclinm.2021.100847","article-title":"Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2).","volume":"35","author":"Castro","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jaci.2021.12.759_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.759_bib25","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jaci.2015.10.010","article-title":"Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis","volume":"136","author":"Bachert","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.759_bib26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921025999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921025999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:35:17Z","timestamp":1758792917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674921025999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0091674921025999"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2021.12.759","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER)","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2021.12.759","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}